Article
Are TYK2 inhibitors JAK inhibitors? Are they effective in PsA? Are they safer than JAKi? Read on to learn more.
All News
Article
One area of continued interest for many rheumatologists is the field of non-radiographic axial spondyloarthritis. Furthermore, the question of the utility of JAK inhibitors for the treatment of axial spondyloarthritis has been on the rise.
Article
At EULAR 2022, I look forward to key topics and presentations in psoriatic arthritis (PsA). Here's a preview of nine studies I'm particularly interested in at this meeting.
Article
Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). Rheumatic complaints may be less frequent than other irAEs associated with ICI in cancer patients.
TheDaoIndex
Tweet
Proof that MTX doesn't affect sperm! Sperm morphology, motility, concentration, semen volume, testosterone/LH/FSH similar b/f and after exposure; DNA fragmentat'n was⬆️in pre-MTX exposure (possible reason high dz activity contributes to infertility) #EULAR2022 @rheumnow OP0131 https://t.co/JWLEggRhAY
TheDaoIndex
Tweet
OP0129 Eudravigilance eval pregnancies exposed to non-TNF biologics compared certolizumab. Possible signal w/#vendolizumab: 3 cases of corpus callosum agenesis (2 Crohn’s, 1 UC, 2 assc w/ other CNS malformations). Belim did not show consistent pattern #EULAR2022 @rheumnow https://t.co/BNKaxu6G0c
Richard Conway
Tweet
Perez-Garcia et al. MTX effect on semen parameters. I still frequently get queries about this. 48 participants here. No significant effect! @RheumNow #EULAR2022 OP0131 https://t.co/33NG6isehm https://t.co/g7Xn33i96u
Richard Conway
Tweet
BIOBADASER Registry data on comparative drug-dependent cancer risk in patients with prior cancer. 352 patients. 32 incident cancers (14 NMSC). No difference between agents, but wide CIs @RheumNow #EULAR2022 OP0138 https://t.co/NEZSL2AQhC https://t.co/EG0NflXXW6
Aurelie Najm
Tweet
Spanish safety registry BIOBADASER 3.0:
*9000+ pts with IMID treated w/ bio or tsDMARDS
*352 pts w/ prior malignancy
*32 incident malignancies
-> 27 events/1000PY
NO diff between ttmts in incidence or mortality but low number pts in non TNFi groups
@RheumNow #EULAR2022
OP0138 https://t.co/8IyC6NdGCF
TheDaoIndex
Tweet
Million $$$ questions presented to Prof T Dorner: anifrolumab vs. belimumab for #SLE? He prefers belimumab d/t more data on multiple organ manifestations ^ it might be protective in pts w/ COVID19 infection. If skin dz is predominant, then anifrolumab #EULAR2022
@rheumnow
Aurelie Najm
Tweet
🚨 Study on MTX and male fertility
Analysis of semen parameters in
🙋🏼♂️HC
🙋🏼♂️RA, PsA and PsO MTX naive
🙋🏼♂️Post MTX
Reassuring data as NO significant effect of MTX was observed on several semen parameters.
#EULAR2022 @RheumNow
OP0131 https://t.co/Fq32lzAMAx
Aurelie Najm
Tweet
RABBIT registry and MACE in RA
No difference between
*JAKi (Tofa and Bari) and *TNFi in both unselected and high CV risks patients.
🧨 different than ORAL surveillance
but Observational and overall Low incidence (28 events).
#EULAR2022 @RheumNow OP0135 https://t.co/o8rngHrwQF
TheDaoIndex
Tweet
Low rates of hypersensitivity reactions (HSR) to #anifrolumab
Pooled data MUSE & TULIP-1/-2 w/1100 pts:
👉1 anaphylaxis (0.15%)
👉12 HSR (3%)
👉43 infusion reaction (9%): N/V/headache
👉most easily treatable w/antihistamine, GCs, acetaminophen
#EULAR2022 POS0708 @rheumnow
Janet Pope
Tweet
#What’sHot? Axial PsA cohort as some drugs seem to work differently in axPsA vs axSpA Less HLAB27+, less male, 17% isolated axial in PsA #OP0026 @RheumNow #EULAR2022 @eular_org https://t.co/I0azSymVrr
Md Yuzaiful Md Yusof
Tweet
#POS0183 #EULAR2022 Pooled analyses of 5 Belimumab RCTs showed better response vs PBO in those:
💠SLEDAI=>10
💠dsDNA+ve + ⬇️C3 and/ ⬇️C4
💠⬇️C3 and/ C4 pre-treatment
💠Response high regardless SDI, Steroid, #lupus duration
@RheumNow https://t.co/fLggazbRQu
Richard Conway
Tweet
MIRACLE (love it!) study. High (max tolerated up to 25mg) vs low dose (6-8mg) MTX in combo with ADA in MTX-IR. Low dose non-inferior with better safety. Japanese population so may not be generalisable. @RheumNow #EULAR2022 OP0062 https://t.co/l3CfzzM7mi https://t.co/lkjuoqLY56
Richard Conway
Tweet
NORD-STAR substudy looking at anticoagulant effects. Important as RA assoc. ⬆️DVT/PE. DMARDs improve haemostatic imbalance, with bDMARDs stronger effect than csDMARD (may relate to better disease control with this) @RheumNow #EULAR2022 OP0059 https://t.co/TKwAZMOZjY https://t.co/IazrfD7z7k
TheDaoIndex
Tweet
Sustained benefits #voclosporin in #LupusNephritis AURORA2 - 2 year study POS0186:
👉no unexpected AEs; rate of AEs⬇️over time
👉COVID19 seen in 12 controls, 7 VCS
👉4 deaths w/control arm vs 0 deaths w/ VCS
👉GFR & sCr & reduction in UPCR remained stable #EULAR2022 @rheumnow
Dr. John Cush
Tweet
Immune Checkpoint Inhibitor Associated Arthritis
Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs).
https://t.co/Eno0TcWlNX https://t.co/XjkBlUEFxk
Eric Dein
Tweet
ACR21: conditionally recommends against steroids with starting csDMARD
#EULAR2022 recommends with rapid GC dose reduction and discontinuation
Which is better recommendation?
@RheumNow
